MedTrace Logo

Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery

NCT01509118 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2012-01-12

No results posted yet for this study

Summary

Arterial and venous thromboembolism represents one of the most common preventable health problems. Patients undergoing surgery, especially hip fracture surgery are at high risk for deep vein thromboembolism (VTE) without thromboprophylaxis. In the absence of prophylaxis, the incidence of fatal pulmonary embolism (PE) after Hip Fracture Surgery (HFS) is reportedly 4%-12%. Provision of thromboprophylaxis to all patients who undergo HFS is recommended.

Conditions

  • Open Fracture of Hip

Sponsors & Collaborators

  • Chulalongkorn University

    collaborator OTHER

  • Chiang Mai University

    collaborator OTHER

  • Thammasat University

    collaborator OTHER

  • Police General Hospital

    collaborator OTHER

  • Saint Louis Hospital,bangkok,Thailand

    collaborator UNKNOWN

  • Bhumibol Adulyadej Hospital

    collaborator OTHER

  • Phramongkutklao College of Medicine and Hospital

    lead OTHER

Principal Investigators

  • Thanainit Chotanaphut, M.D. · Department of Orthopaedic Surgery Pharmongkutklao Hospital

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-06-30
Completion
2013-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01509118 on ClinicalTrials.gov